Your browser doesn't support javascript.
loading
Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10.
Ghadjar, Pirus; Hayoz, Stefanie; Bernhard, Jürg; Zwahlen, Daniel R; Hölscher, Tobias; Gut, Philipp; Guckenberger, Matthias; Hildebrandt, Guido; Müller, Arndt-Christian; Plasswilm, Ludwig; Papachristofilou, Alexandros; Stalder, Lukas; Biaggi-Rudolf, Christine; Sumila, Marcin; Kranzbühler, Helmut; Najafi, Yousef; Ost, Piet; Azinwi, Ngwa C; Reuter, Christiane; Bodis, Stephan; Kaouthar, Khanfir; Wust, Peter; Thalmann, George N; Aebersold, Daniel M.
Afiliación
  • Ghadjar P; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Hayoz S; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Bernhard J; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Zwahlen DR; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Hölscher T; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Gut P; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Guckenberger M; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Hildebrandt G; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Müller AC; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Plasswilm L; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Papachristofilou A; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Stalder L; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Biaggi-Rudolf C; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Sumila M; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Kranzbühler H; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Najafi Y; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Ost P; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Azinwi NC; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Reuter C; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Bodis S; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Kaouthar K; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Wust P; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Thalmann GN; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
  • Aebersold DM; Pirus Ghadjar, Jürg Bernhard, George N. Thalmann, and Daniel M. Aebersold, Inselspital, Bern University Hospital, and University of Bern; Stefanie Hayoz, Lukas Stalder, and Christine Biaggi-Rudolf, Swiss Group for Clinical Cancer Research Coordinating Center; Jürg Bernhard, International Breast Canc
J Clin Oncol ; 33(35): 4158-66, 2015 Dec 10.
Article en En | MEDLINE | ID: mdl-26527774
ABSTRACT

PURPOSE:

Patients with biochemical failure (BF) after radical prostatectomy may benefit from dose-intensified salvage radiation therapy (SRT) of the prostate bed. We performed a randomized phase III trial assessing dose intensification. PATIENTS AND

METHODS:

Patients with BF but without evidence of macroscopic disease were randomly assigned to either 64 or 70 Gy. Three-dimensional conformal radiation therapy or intensity-modulated radiation therapy/rotational techniques were used. The primary end point was freedom from BF. Secondary end points were acute toxicity according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0) and quality of life (QoL) according to the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires C30 and PR25.

RESULTS:

Three hundred fifty patients were enrolled between February 2011 and April 2014. Three patients withdrew informed consent, and three patients were not eligible, resulting in 344 patients age 48 to 75 years in the safety population. Thirty patients (8.7%) had grade 2 and two patients (0.6%) had grade 3 genitourinary (GU) baseline symptoms. Acute grade 2 and 3 GU toxicity was observed in 22 patients (13.0%) and one patient (0.6%), respectively, with 64 Gy and in 29 patients (16.6%) and three patients (1.7%), respectively, with 70 Gy (P = .2). Baseline grade 2 GI toxicity was observed in one patient (0.6%). Acute grade 2 and 3 GI toxicity was observed in 27 patients (16.0%) and one patient (0.6%), respectively, with 64 Gy, and in 27 patients (15.4%) and four patients (2.3%), respectively, with 70 Gy (P = .8). Changes in early QoL were minor. Patients receiving 70 Gy reported a more pronounced and clinically relevant worsening in urinary symptoms (mean difference in change score between arms, 3.6; P = .02).

CONCLUSION:

Dose-intensified SRT was associated with low rates of acute grade 2 and 3 GU and GI toxicity. The impact of dose-intensified SRT on QoL was minor, except for a significantly greater worsening in urinary symptoms.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Asunto principal: Prostatectomía / Neoplasias de la Próstata / Trastornos Urinarios / Biomarcadores de Tumor / Terapia Recuperativa / Antígeno Prostático Específico / Radioterapia Conformacional / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Asunto principal: Prostatectomía / Neoplasias de la Próstata / Trastornos Urinarios / Biomarcadores de Tumor / Terapia Recuperativa / Antígeno Prostático Específico / Radioterapia Conformacional / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Año: 2015 Tipo del documento: Article